Provides comprehensive understanding and unprecedented access to
discovery, preclinical and clinical stage partnering agreements entered
into by the worlds leading biopharma companies
The Discovery, Preclinical and Clinical Stage Partnering Terms and
Agreements in Pharma and Biotech report provides comprehensive
understanding and unprecedented access to the discovery, preclinical and
clinical stage partnering deals and agreements entered into by the
worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how
and why companies enter discovery, preclinical and clinical stage
partnering deals. The majority of deals are where the licensee obtains a
right or an option right to license the licensors product or compound.
These deals tend to be multicomponent, starting with collaborative
R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated
deals terms provides critical insight into the negotiation process in
terms of what you can expect to achieve during the negotiation of terms.
Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are
triggered – contract documents provide this insight where press releases
do not.
This report contains over 8,000 links to online copies of actual
discovery, preclinical and clinical stage deals and contract documents
as submitted to the Securities Exchange Commission by companies and
their partners. Contract documents provide the answers to numerous
questions about a prospective partner’s flexibility on a wide range of
important issues, many of which will have a significant impact on each
party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation
of discovery, preclinical and clinical stage deal making and business
activities.
Chapter 1 provides an introduction to the report, whilst
Chapter 2 provides an overview of why companies partner discovery, preclinical and clinical stage compounds/products.
Chapter 3 provides an overview of discovery,
preclinical and clinical stage deals strategy and deal structure
including numerous case studies.
Chapter 4 provides an overview of the various payment strategies used in discovery, preclinical and clinical stage deals.
Chapters 5 to 7 provide a review of discovery,
preclinical and clinical stage deal making since 2007. Deals are listed
by headline value, signed by bigpharma, most active bigpharma, and most
active of all biopharma companies. Where the deal has an agreement
contract published at the SEC a link provides online access to the
contract.
Chapter 8 provides a detailed analysis of
discovery, preclinical and clinical stage payment terms including
average headline, upfront, milestone and royalty rates for discovery
deals.
Chapter 9 provides a review of the leading discovery, preclinical and clinical stage deal by headline value.
Chapter 10 provides a comprehensive listing of the
top 50 big pharma and big biotech companies with a brief summary
followed by a comprehensive listing of discovery, preclinical and
clinical stage deals, as well as contract documents available in the
public domain. Where available, each deal title links via Weblink to an
online version of the actual contract document, providing easy access to
each contract document on demand.
Chapters 11 to 13 provides a comprehensive and
detailed review of discovery, preclinical and clinical stage partnering
deals signed and announced since 2007, where a contract document is
available in the public domain. The chapter is organized by company A-Z,
stage of development at signing, deal type (collaborative R&D,
co-promotion, licensing etc), and specific therapy focus. Each deal
title links via Weblink to an online version of the deal record and
where available, the contract document, providing easy access to each
contract document on demand.
The report also includes numerous tables and figures that
illustrate the trends and activities in discovery, preclinical and
clinical stage partnering and deal making since 2007.
In addition, a comprehensive appendix is provided organized by
partnering company A-Z, deal type, therapy focus and technology type.
Each deal title links via Weblink to an online version of the deal
record and where available, the contract document, providing easy access
to each contract document on demand.
In conclusion, this report provides everything a prospective
dealmaker needs to know about partnering in the research, development
and commercialization of discovery, preclinical and clinical stage
products and compounds.
Latest
Report:
The Companion Diagnostics Partnering
Terms and Agreements report provides comprehensive understanding and
unprecedented access to the companion diagnostics partnering deals and
agreements entered into by the worlds leading healthcare companies. The
report provides a detailed understanding and analysis of how and why companies
enter companion diagnostic partnering deals. The majority of deals are
discovery or development stage whereby the licensee obtains a right or an
option right to license the licensors companion diagnosti...
